Company
United Therapeutics
United Therapeutics has 220 drugs tracked on RxWires: 13 post-market, 9 approved, 31 in Phase 3, 7 in Phase 2/3, 70 in Phase 2, 22 in Phase 1/2, 60 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Valganciclovir | Post-Market | Cytomegalovirus Disease |
| Levocetirizine | Post-Market | Allergic Rhinitis |
| Levetiracetam, Keppra | Post-Market | Memory Loss Associated With Corticosteroid Use |
| treprostinil sodium | Post-Market | Hypertension, Pulmonary |
| Remodulin | Post-Market | Pulmonary Arterial Hypertension |
| Maribavir | Post-Market | Transplant Complication |
| escitalopram and tramadol | Post-Market | Healthy |
| Ferric carboxymaltose | Post-Market | Anemia, Iron Deficiency |
| Contrave | Post-Market | Obesity |
| Fampridine-SR | Post-Market | Multiple Sclerosis |
| Arformoterol tartrate | Post-Market | Chronic Obstructive Pulmonary Disease |
| Slow Dose Titration Group of Subcutaneous Treprostinil | Post-Market | Pulmonary Arterial Hypertension |
| low calorie, low nitrogen parenteral nutrition for patient with NRS score 3 | Post-Market | Gastrointestinal Neoplasms |
| PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN | Approved | |
| STARJEMZA | Approved | |
| CHLORTHALIDONE | Approved | |
| AMITRIPTYLINE HYDROCHLORIDE | Approved | |
| AZELAIC ACID | Approved | |
| PALBOCICLIB CAPSULES | Approved | |
| DIPHENHYDRAMINE HYDROCHLORIDE | Approved | |
| DOXYCYCLINE HYCLATE | Approved | |
| LORAZEPAM | Approved | |
| Alirocumab 150 MG/ML [Praluent] | Phase 3 | Hemodialysis |
| Rivaroxaban 10 MG | Phase 3 | Covid19 |
| efgartigimod administration | Phase 3 | Myasthaenia Gravis |
| inhaled treprostinil | Phase 3 | Pulmonary Arterial Hypertension |
| LY3819253 | Phase 3 | Covid19 |
| Volanesorsen | Phase 3 | Familial Chylomicronemia Syndrome |
| Oral treprostinil (UT-15C) Sustained Release Tablets | Phase 3 | Pulmonary Hypertension |
| navenibart | Phase 3 | Hereditary Angioedema (HAE) |
| Factor IX (rFIXFc) | Phase 3 | Severe Hemophilia B |
| mipomersen sodium | Phase 3 | Heterozygous Familial Hypercholesterolemia |
| HEPLISAV-B | Phase 3 | HIV Infection |
| MP0420 | Phase 3 | COVID-19 |
| Almonertinib | Phase 3 | Non Small Cell Lung Cancer |
| Pitavastatin | Phase 3 | HIV |
| Treprostinil Diolamine | Phase 3 | Pulmonary Arterial Hypertension |
| Intranasal challenge drug | Phase 3 | Heroin Dependence |
| rFIXFc | Phase 3 | Hemophilia B |
| HMPL-004 | Phase 3 | Ulcerative Colitis |
| Surufatinib | Phase 3 | Neuroendocrine Tumors |
| Ralinepag | Phase 3 | PAH |
| rFVIIIFc | Phase 3 | Severe Hemophilia A |
| MELT-300 sublingual tablet | Phase 3 | Cataract |
| Factor VIII (rFVIIIFc) | Phase 3 | Severe Hemophilia A |
| Plozasiran | Phase 3 | Familial Chylomicronemia Syndrome |
| Perindopril | Phase 3 | Essential Hypertension |
| 6% Hydroxy-ethyl starch (130/0.4) | Phase 3 | Intensive Care |
| fruquintinib +paclitaxel | Phase 3 | Advanced Gastric Cancer |
| Savolitinib | Phase 3 | Non-small Cell Lung Cancer Metastatic |
| Racecadotril | Phase 3 | Diarrhea |
| Ponatinib 30 mg QD | Phase 3 | Chronic Phase Chronic Myeloid Leukemia |
| Minodronic acid hydrate | Phase 3 | Involutional Osteoporosis |
| alpha-1-Proteinase Inhibitor | Phase 2/3 | HIV Disease |
| α1 Proteinase Inhibitor | Phase 2/3 | HIV Disease |
| Reslizumab | Phase 2/3 | Eosinophilic Esophagitis |
| treprostinil SMI (treprostinil inhalation spray) | Phase 2/3 | Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease |
| Prednisolone | Phase 2/3 | Allergic Bronchopulmonary Aspergillosis |
| H. pylori treatment | Phase 2/3 | Iron Deficiency Anemia |
| Fragmin (dalteparin) | Phase 2/3 | Thromboembolism |
| Nivolumab | Phase 2 | Squamous Cell Carcinoma of the Head and Neck |
| DFMO | Phase 2 | Prostate Cancer |
| Enfortumab Vedotin | Phase 2 | Metastatic Colorectal Cancer |
| defibrotide | Phase 2 | Veno-occlusive Disease |
| Trastuzumab deruxtecan | Phase 2 | Gastrooesophageal Cancer |
| intramyocardial injection of VEGF-A165/bFGF:placebo plasmid | Phase 2 | Coronary Artery Disease |
| Ruxolitinib | Phase 2 | Myelodysplastic/Myeloproliferative Neoplasm |
| NV-5138 | Phase 2 | Major Depressive Disorder |
| Zimberelimab | Phase 2 | Hepatobiliary Cancer |
| Fruquintinib | Phase 2 | Lung Cancer |
| Pasireotide Long Acting Release (LAR) | Phase 2 | Neuroendocrine Tumors |
| Cabozantinib 80 MG | Phase 2 | RCC |
| Molnupiravir 200 mg | Phase 2 | SARS-CoV-2 Infection, COVID-19 |
| Psilocybin | Phase 2 | Body Dysmorphic Disorders |
| Pegylated Interferon-alpha 2a, 180 mcg/week sc | Phase 2 | HIV Infections |
| Ivabradine | Phase 2 | Lymphoma |
| Ponatinib | Phase 2 | GIST |
| Bifeprunox | Phase 2 | Bipolar I Disorder |
| Eculizumab | Phase 2 | Membranoproliferative Glomerulonephritis |
| Cabozantinib 40 MG oral once a day | Phase 2 | Cervical Cancer |
| Pemigatinib | Phase 2 | Intrahepatic Cholangiocarcinoma |
| SARS-CoV-2 mRNA Vaccine ARCT-021 | Phase 2 | Hematopoietic and Lymphatic System Neoplasm |
| Erlotinib | Phase 2 | Ependymoma |
| PTI-125, 100 mg tablets | Phase 2 | Alzheimer Disease |
| SU011248, Sutent | Phase 2 | Papillary Thyroid Cancer |
| Filgotinib | Phase 2 | Inflammatory Bowel Disease |
| MEN1703 | Phase 2 | Non-Hodgkin Lymphoma, B-cell |
| Apatinib | Phase 2 | Nasopharyngeal Neoplasms |
| PRT064445/Enoxaparin | Phase 2 | Healthy Volunteers |
| Anti-CD40 Agonist Monoclonal Antibody CDX-1140 | Phase 2 | Ovarian Clear Cell Adenocarcinoma |
| Cabozantinib S-malate | Phase 2 | Poorly Differentiated Thyroid Gland Carcinoma |
| ISIS 678354 | Phase 2 | Hypertriglyceridemia |
| Adalimumab | Phase 2 | Dupuytren's Disease |
| IMAB362 | Phase 2 | Solid Tumors |
| Liposome-encapsulated Daunorubicin-Cytarabine | Phase 2 | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome |
| Bemarituzumab | Phase 2 | Gastric Cancer |
| Umbralisib | Phase 2 | Chronic Lymphocytic Leukemia |
| Dinutuximab Beta, Zoledronic acid, Interleukin-2 | Phase 2 | Leiomyosarcoma |
| Favipiravir | Phase 2 | COVID-19 |
| decitabine (5-aza-2'deoxycytidine) | Phase 2 | Chronic Myelogenous Leukemia |
Latest
- united therapeutics filed 8-K
- Label updated: AZELAIC ACID
- united therapeutics filed 8-K
- united therapeutics filed 8-K
- united therapeutics filed 8-K
Follow United Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.